Article Index


A Biotech Stock to Buy with "Nearly Limitless" Profit Potential


Today, we're recommending a biotech stock to buy that Money Morning Biotech Investing Specialist Ernie Tremblay says has a "nearly limitless" profit potential.

It's a medical device company with a revolutionary product that helps restore vision to people suffering from blindness.

Here's the revolutionary technology behind this biotech stock to buy...

This Cannabis Biotech Leader Helped Us Beat the Market by More Than 620%


Back on March 27, 2014, I recommended that Money Morning Members pick up what I felt was the very best play in the burgeoning cannabis biotech industry.

Today, the shares have done even better than I imagined, which is why I wanted to touch base with you again.

And if you missed this stock last year - no worries. We'll start you now as it continues its run - a run that took off while "popular" medical marijuana stocks cratered.

Here's how we'll do it...

Navigating the Shoals of an Overvalued Market


Stocks have struggled to rally in recent weeks, but that hasn't stopped the IPO market from offering investors the chance to leave reason behind.

Last week, two particular deals demonstrated that while the overall market is expensive, pockets of it are undeniably in a bubble.

Here's what you should know about the IPOs and the week...

Here's what you should know about the IPOs and the week...

"21st Century Cures" Could Revolutionize Biotech

Medicine Pills Stacked Like Increasing Graph on Newly Designed U.S. One Hundred Dollar Bills.

No one is thrilled with the way new drugs and medical devices come to market in the U.S. - not the biotech and pharmaceutical companies, not the regulators at the Food and Drug Administration (FDA) or National Institutes of Health (NIH), not physicians, and certainly not patients desperately in need of new therapies.

The process is hugely expensive and incredibly slow. According to the Tuft's Center for the Study of Drug Development, the average cost of bringing a new prescription drug from lab to market now tops $2.5 billion and takes more than 10 years.

That can make for a real thrill ride where investors are concerned, as share price for a pre-profit biotech can rise and fall dramatically and unpredictably with every related data release, financial report, news item, or regulatory hiccup over an entire decade, making long-term investment a crapshoot, at best.

But new regulations on the table could change everything for biotech investors and critically ill patients...

Biotech Investing for Beginners: Your 7-Step Guide

Biotech news

Biotech investing can be tricky. The industry is complicated, and the stocks are volatile.

But the profit payoff can be life-changing.

That's why we've created the "Biotech Investing for Beginners Guide" with Money Morning's Biotech Investing Specialist Ernie Tremblay.

That's because many of the metrics we use to evaluate other stocks - like P/E ratio, profit margin, earnings per share - don't always apply to biotech stocks.

Here's Tremblay's step-by-step guide to investing in biotech stocks...

Two Divergent Northbound Stocks to Buy Right Now


I want to spend today talking to you about two stocks that we've repeatedly recommended to Private Briefing readers.

Both stocks made bullish headlines last week.

One of the stocks is a winner - a big winner, in fact. And the other has been a loser - so far.

But we're predicting it will be a big winner, too - a huge winner.

And last week's developments strengthened our case...

3 of the Best Biotech Stocks to Buy Today

best biotech stocks

If you're looking for the best biotech stocks on the market, you've come to the right place.

Our biotech specialists aren't considered to be among the best... they are the best.

And they picked three of the best biotech stocks to profit from today...

5 Pharmaceutical Stocks to Avoid

pharmaceutical stocks

Pharmaceutical stocks can plummet for myriad reasons: loss of funding, lawsuits, poor clinical trials.

It's a risky sector to get yourself involved in - one with big rewards. But, where there are big rewards, there are also big losses.

We took a look at five pharmaceutical stocks you should avoid...

Six Pharmaceutical Stocks That Outperformed the Rest in 2014

pharmaceutical stocks

Pharmaceutical stocks soar when their companies receive FDA approval. The key to investing in the pharmaceutical sector is research: you've got to know when, how and if the company you like will profit.

That's why we've compiled a list of the leading pharmaceutical stocks around.

Have a look at these drug companies yielding impressive gains while they treat diseases...

One Stock That Will Profit from a New, Breakthrough Medical Direction

Medical doctor male

Modern medicine, for all of its sophisticated drugs, complex gadgets, and amazing surgical procedures, rarely cures anything. It treats. It manages. It postpones the inevitable.

But return a patient to normal, optimal health?


So when an innovation comes along that can effect a complete and permanent remission of disease or restore damaged organs to a pristine state, it should cause your keenest investing instincts to perk up and pay attention...

This New Alzheimer's Drug Could Be the Fastest Route to a Treatment Breakthrough

new Alzheimer’s drug

Just last week, two major pharmaceutical companies announced that they are working together on a new Alzheimer's drug - and that's great news. But it may be a decade away from becoming reality.

But another biotech company is zooming ahead in the race for the cure - and its drug is in late-stage phase 3 trials.

In other words, there is a way to both fight Alzheimer’s and supercharge your portfolio – today…

The BioScience Profit Outlook for the Rest of 2014

With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.

That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.

That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.

Today I want to share with you some of my thinking, expectations, and predictions, as well as my strategy to get us tapped in to a segment of the bioscience market we haven't even touched yet.

This segment has been tremendously profitable for some of the world's biggest drug companies, and I think there are going to be some killer profits for us there, too... Full Story

How to Tap Big Profits in That "Other" Bioscience Niche

At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if you don't have someone knowledgeable to guide you.

And it's true. Putting your money behind new, experimental drugs, without some guidance, is a crapshoot.

But there's an approach to making profits from this sector that doesn't rely on breakthrough discoveries, expensive drug trials, or constant cash infusions through dilutive public offerings to fuel its engine.

That's what makes the company we'll look at today such an attractive investment.

Welcome to the lucrative world of generics...

Full Story

Best Stocks to Buy: Cash In on a New $35 Billion Biotech Market

best stocks to buy

Each week our Money Morning experts dish out the latest profit plays - and asset-protection moves - for our Money Morning Members - all for free.

Last week, Money Morning's best stocks to buy included five biotech picks. Four of them are blazing trails in immuno-oncology. Our fifth biotech pick has already tripled in value in the last six months, and it's not done yet.

Aside from these biotech winners, we covered an ETF play on the European Central Bank's recent policy changes, the best stock in "unified computing," and a smart gold buy at a discount.

Get these plus more of our latest, best stocks to buy.

The Four Telltale Signs of a Bioscience "Blockbuster" in the Making

The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.

They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."

And this is how you find them... Full Story

© 2015 Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201, Email: